TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00883727
Drug: Plasmalyte A
Normalized name: PLASMALYTE A
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01126424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT03909217
Drug: Insomnia medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For patients with severe insomnia, stabilizers and benzodiazepines could be prescribed and must be recorded in the case report form.
Study: NCT00426270
Drug: Octagam 10%
Normalized name: Octagam 10% Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octagam 10% was supplied as a ready-to-use solution in glass bottles.
Study: NCT03421431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets daily for 12 weeks
Study: NCT03453632
Drug: Botulinic toxin
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of botulinic toxin (200 UI) on right or left foot
Study: NCT03453632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of physiological serum (200 UI) on right or left foot
Study: NCT04923152
Drug: moderate statin dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg rosuvastatin per day
Study: NCT04923152
Drug: high dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg rosuvastatin per day
Study: NCT01030146
Drug: NeilMed® Sinus Rinse™ System with Isotonic Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
Study: NCT01669239
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles of:~* Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~* Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~* Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~* Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks
Study: NCT00079937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.
Study: NCT02057770
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00527059
Drug: spironolactone, beta-blockers,ecc
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04111315
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibufen-L® tablets 500 mg 2-2-2
Study: NCT00031447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical to oral acyclovir suspension in appearance and taste.
Study: NCT00554164
Drug: (R-)CHOP protocol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone).
Study: NCT00554164
Drug: (R-)CHOP protocol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with a negative interim-PET scan assigned to arm A1 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone). Arm A1 was closed when the number of patients required for the randomisation between arms A1 and A2 was reached.
Study: NCT00554164
Drug: (R-)CHOP protocol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with a negative interim-PET scan assigned to arm A2 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) plus two additional doses rituximab. Since the number of patients required for the randomisation between arms A1 and A2 has been reached, all patients with a negative interim-PET scan are treated according to arm A2.
Study: NCT04559308
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line neoadjuvant chemotherapy protocol
Study: NCT00829582
Drug: ETI-204, Anthim
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous infusion of 120, 240 or 360 mg of ETI-204
Study: NCT00041262
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01323660
Drug: GSK573719/GW642444 125/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125mcg/ 25mcg QID (Once daily , inhaled)
Study: NCT01323660
Drug: GSK573719/GW642444 62.5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: 62.5mcg/25mcg QID
Study: NCT01323660
Drug: GSK573719 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125mcg QID
Study: NCT03950882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT00002556
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02590263
Drug: ABT-414
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-414 will be administered by intravenous infusion
Study: NCT03437278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0 mg per 1 ml liquid injection once every 4 weeks.
Study: NCT01128738
Drug: GSK1358820
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onabotulinum toxin type A
Study: NCT01128738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01995383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administrations
Study: NCT01995383
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 single oral administrations
Study: NCT01995383
Drug: RO6836191
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered, single ascending doses
Study: NCT01995383
Drug: RO6836191
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 single oral doses
Study: NCT01995383
Drug: RO6836191
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT00455325
Drug: Active Comparator: Second Intervention (3 weeks)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily 80mg chloroquine or placebo tablet 3 Weeks followed by euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Study: NCT00455325
Drug: Active Comparator: Third Intervention (3 weeks)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily 80mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Study: NCT00455325
Drug: Active Comparator: Fourth Intervention (3 weeks)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily 250mg tablet for 3 weeks followed by: euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
Study: NCT00501631
Drug: Placebo for VIVITROL 380 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via IM injection once every 4 weeks.
Study: NCT00165139
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Described under detailed description
Study: NCT00180687
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised Normal Saline
Study: NCT00490009
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: As premedication 30 to 60 minutes before antibody infusion; 650 mg, oral. Used to as to relieve pain
Study: NCT00051311
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
Study: NCT01078675
Drug: rosuvastatin calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg, oral, once daily, 24 months
Study: NCT01078675
Drug: rosuvastatin calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg, oral, once daily, 24 months
Study: NCT01078675
Drug: rosuvastatin calcium
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg, oral, once daily, 24 months
Study: NCT00051311
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recipients will receive induction therapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. One cycle is 5 days on drug therapy followed by a 16 day rest period.
Study: NCT00051311
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD)..
Study: NCT02159196
Drug: acetylcysteine and salbutamol
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: routine nebulisation of a 3 mL-solution of acetylcysteine (fluimucil 100mg/ml) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml) four times daily
Study: NCT03628079
Drug: ReposMBZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules 50mg, 100mg, 200mg
Study: NCT01543165
Drug: Ketorolac and nefopam balanced analgesia
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intravenous administration of ketorolac and nefopam
Study: NCT01543165
Drug: Balanced analgesia using ketorolac and morphine
Normalized name: phenylephrine and ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intravenous administration of ketorolac and morphine
Study: NCT01543165
Drug: Pain control with single analgesics (ketorolac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm do not use balanced analgesia. Instead, ketorolac IV administration followed by 50cc normal saline administration (for blinding) will be used in this group.
Study: NCT02683941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.
Study: NCT02683941
Drug: Best Supportive Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best Supportive Care is best available therapy at the choice of the investigator
Study: NCT00761098
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
Study: NCT00761098
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% Salt Poor Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
Study: NCT01868568
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose administered subcutaneously (s.c., under the skin).
Study: NCT00587665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline given of equal volume to drug
Study: NCT03703895
Drug: Topical AFX5931
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule.
Study: NCT03861377
Drug: Remifentanil R2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,7 microg/kg
Study: NCT03861377
Drug: Remifentanil R4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,1 microg/kg
Study: NCT03861377
Drug: Remifentanil R8
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,7 microg/kg
Study: NCT03703895
Drug: Topical Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator, Topical Placebo.
Study: NCT00102609
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1
Study: NCT03908242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
Study: NCT00714233
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to the active metformin arm. 2 capsules BID x 24 weeks.
Study: NCT02730962
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin 3 times a day for 5 days
Study: NCT01272804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
Study: NCT01894958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry flavored solution
Study: NCT00856180
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00984867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet
Study: NCT04876534
Drug: MethylPREDNISolone Injectable Solution
Normalized name: methylprednisolone Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT02900716
Drug: DTRMWXHS-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTRMWXHS-12
Study: NCT02900716
Drug: DTRM-505
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTRMWXHS-12 and everolimus
Study: NCT02900716
Drug: DTRM-555
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTRMWXHS-12 and everolimus and pomalidomide
Study: NCT01145144
Drug: dehydroepiandrosterone crystalline fine powder
Normalized name: Mesembryanthemum crystallinum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01668797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator for 52 weeks
Study: NCT00406653
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months
Study: NCT01257165
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg per 70 kg body weight, given orally as a single dose
Study: NCT01257165
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill identical to zopiclone pill, given orally as a single dose
Study: NCT01257165
Drug: Placebo drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink, given orally as a single dose
Study: NCT04865562
Drug: 0.5% cholorbutanol, saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg 0.5% cholorbutanol, 50mg saline
Study: NCT00483262
Drug: CCI-779
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles
Study: NCT00558753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Given 2 hours prior to surgery, and twice a day for 14 postoperative days.
Study: NCT00377598
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
Study: NCT01118611
Drug: Aurora B/C kinase inhibitor GSK1070916A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01794923
Drug: IBU BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days
Study: NCT01794923
Drug: Placebo BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days
Study: NCT01794923
Drug: Placebo TID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days
Study: NCT00487721
Drug: Silibin-Phytosome
Normalized name: silybin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take Silibin-Phytosome for 2-10 weeks. The dose of Silibin-Phytosome is 13 grams daily, in three divided doses. Patients will be asked to mix 1 level teaspoon and 1 heaping ¼ teaspoon of Silybin-Phytosome powder into 6 tablespoons of applesauce for each dose.
Study: NCT00918190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT00530777
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo twice daily from 34 weeks gestation to 1 year postpartum
Study: NCT01210079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo titrated over 1 week with established dose taken daily for 5 weeks.
Study: NCT04296240
Drug: Oxaliplatin and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive 5-Fu and oxaliplatin based neoadjuvant chemotherapy for 3 months
Study: NCT00106145
Drug: Comparator: MK0752, Notch Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalating beginning with rising dose levels of 300, 450, and 600 mg/day in a continuous dosing schedule.
Study: NCT00106145
Drug: Comparator: MK0752, Notch Inhibitor - 450 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 450 mg capsules daily for 28 day cycles.
Study: NCT00106145
Drug: Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalating in a repeating intermittent dosing schedule of 3 days on and 4 days off at rising dose levels of 450, 600, 800, 1000, 1200, and 1400 mg/day.
Study: NCT00106145
Drug: Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments.
Study: NCT01513356
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.
Study: NCT00106145
Drug: Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION
Study: NCT00182403
Drug: UFH 250 U/kg or LMWH 100 U/kg sc twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02668185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01013597
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.
Study: NCT01110941
Drug: S-1, leucovorin, oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1(20mg、25mg), capsule, 40\~60mg, Bid,p.o., day1\~7； LV (25 mg), tablet, 25mg,Bid,p.o., day1\~7； L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.
Study: NCT00626639
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous (IV) bolus injection
Study: NCT02525068
Drug: AZD5363
Approvals — FDA: no, EMA: no, PMDA: no
Description: Until confirmed disease progression.
Study: NCT04780321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 patients receipt placebo intravenous infusion on day 1
Study: NCT02387086
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03253926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule BID
Study: NCT01602523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaler once daily 28 days
Study: NCT01438684
Drug: RPh201
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microliter s.c. twice a week for 3 months
Study: NCT00434434
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous repeating dose
Study: NCT02463643
Drug: Z-215 10mg
Normalized name: zinc pyrithione 10 MG/ML [Theraplex Z]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z-215 10mg, capsules
Study: NCT02463643
Drug: Z-215 20mg
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Z-215 20mg, capsules
Study: NCT00687700
Drug: GSK961081
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.
Study: NCT00687700
Drug: GSK961081 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.
Study: NCT02463643
Drug: Z-215 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z-215 placebo-matching capsules
Study: NCT04005053
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02544217
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01637623
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule daily for 6 weeks
Study: NCT03883386
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via capsule
Study: NCT04386343
Drug: CH1701 for prevention and treatment of radiation burns.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ch1701 is used for cancer patients who are treated with radiotherapy, then assess the safety and treatment effectiveness of the product.